How does US Patent Law account for AI-assisted Biopharma Innovation? How do we deal with the traditional Inventorship theory to AI-based algorithm that designs a new drug or identifies a novel drug target? Who gets Inventorship?
How does US Patent Law account for AI-assisted Biopharma Innovation? How do we deal with the traditional Inventorship theory to AI-based algorithm that designs a new drug or identifies a novel drug target? Who gets Inventorship?